Drug Report History

Return to report

Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.

The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.

Version v3-EN Version v5-FR
Language English French
Date Updated 2024-04-01 2024-05-17
Drug Identification Number 02457482 02457482
Brand name ADENOSINE INJECTION ADENOSINE INJECTION
Common or Proper name ADENOSINE INJECTION ADENOSINE INJECTION
Company Name FRESENIUS KABI CANADA LTD FRESENIUS KABI CANADA LTD
Ingredients ADENOSINE ADENOSINE
Strength(s) 3MG 3MG
Dosage form(s) SOLUTION SOLUTION
Route of administration INTRAVENOUS INTRAVENOUS INTRAVENOUS INTRAVENOUS
Packaging size 4 mL 4 mL
ATC code C01EB C01EB
ATC description OTHER CARDIAC PREPARATIONS OTHER CARDIAC PREPARATIONS
Reason for shortage Demand increase for the drug. Demand increase for the drug.
Anticipated start date 2024-03-31 2024-03-31
Actual start date
Estimated end date 2024-05-15 2024-05-15
Actual end date 2024-05-17
Shortage status Actual shortage Actual shortage
Tier 3 Status No No
Company comments Fresenius Kabi Canada regrets to advise that due to increase demand, we will be encountering a supply interruption on our Adenosine Injection 3 mg/mL Prefilled syringe 4 mL effective March 31, 2024, until May 15, 2024. During this time, our Adenosine Injection 3 mg/mL Prefilled syringe 2 mL will be available for substitution. Fresenius Kabi Canada regrets to advise that due to increase demand, we will be encountering a supply interruption on our Adenosine Injection 3 mg/mL Prefilled syringe 4 mL effective March 31, 2024, until May 15, 2024. During this time, our Adenosine Injection 3 mg/mL Prefilled syringe 2 mL will be available for substitution.
Health Canada comments